MX2019014430A - Human antibodies to bet v 1 and methods of use thereof. - Google Patents
Human antibodies to bet v 1 and methods of use thereof.Info
- Publication number
- MX2019014430A MX2019014430A MX2019014430A MX2019014430A MX2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- bet
- fagales
- allergens
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000013566 allergen Substances 0.000 abstract 4
- 241000219427 Fagales Species 0.000 abstract 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 210000003651 basophil Anatomy 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 235000018185 Betula X alpestris Nutrition 0.000 abstract 1
- 235000018212 Betula X uliginosa Nutrition 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513872P | 2017-06-01 | 2017-06-01 | |
| US201762571696P | 2017-10-12 | 2017-10-12 | |
| US201862662165P | 2018-04-24 | 2018-04-24 | |
| PCT/US2018/035366 WO2018222854A1 (en) | 2017-06-01 | 2018-05-31 | Human antibodies to bet v 1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014430A true MX2019014430A (en) | 2020-07-14 |
Family
ID=62705709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014430A MX2019014430A (en) | 2017-06-01 | 2018-05-31 | Human antibodies to bet v 1 and methods of use thereof. |
| MX2023000390A MX2023000390A (en) | 2017-06-01 | 2019-11-29 | Human antibodies to bet v 1 and methods of use thereof. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000390A MX2023000390A (en) | 2017-06-01 | 2019-11-29 | Human antibodies to bet v 1 and methods of use thereof. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10793624B2 (en) |
| EP (1) | EP3630814A1 (en) |
| JP (3) | JP6963036B2 (en) |
| KR (2) | KR20210143327A (en) |
| CN (1) | CN110997713B (en) |
| AU (2) | AU2018275657B2 (en) |
| BR (1) | BR112019025150B1 (en) |
| CA (1) | CA3063588A1 (en) |
| CL (3) | CL2019003508A1 (en) |
| CO (1) | CO2019013196A2 (en) |
| IL (2) | IL270894B2 (en) |
| MX (2) | MX2019014430A (en) |
| NZ (1) | NZ759513A (en) |
| PH (1) | PH12019550238A1 (en) |
| WO (1) | WO2018222854A1 (en) |
| ZA (1) | ZA201907513B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210143327A (en) | 2017-06-01 | 2021-11-26 | 리제너론 파마슈티칼스 인코포레이티드 | Human antibodies to bet v 1 and methods of use thereof |
| IL299207A (en) | 2020-07-01 | 2023-02-01 | Regeneron Pharma | Methods of treating allergy using anti-bet v 1 antibodies |
| CN113041271B (en) * | 2021-04-14 | 2022-12-27 | 浙江养生堂天然药物研究所有限公司 | Composition with preventing and antiallergic effects |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010194A2 (en) | 1992-10-27 | 1994-05-11 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the fagales order |
| JPH08501799A (en) | 1992-12-21 | 1996-02-27 | タノックス バイオシステムズ インコーポレイテッド | Allergen-specific IgA monoclonal antibody and related substances for treating allergy |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ITMI20052517A1 (en) * | 2005-12-29 | 2007-06-30 | Lofarma Spa | VARIANBTIO HYPOALLERGENICS OF ALLERGENE GREATER BET V 1 BERRY OF BETULA VERRUCOSA |
| AT503297B1 (en) | 2006-05-18 | 2007-09-15 | Biomay Ag | Use of antibody or its derivative for preparation of medicament for passive immunization of individual for preventing and/or treating allergic reactions in individual caused by exposure to birch pollen allergen |
| MX2008014804A (en) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor. |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| US10935554B2 (en) * | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| KR20210143327A (en) | 2017-06-01 | 2021-11-26 | 리제너론 파마슈티칼스 인코포레이티드 | Human antibodies to bet v 1 and methods of use thereof |
| AU2019307928A1 (en) | 2018-07-19 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof |
-
2018
- 2018-05-31 KR KR1020217037411A patent/KR20210143327A/en active IP Right Grant
- 2018-05-31 WO PCT/US2018/035366 patent/WO2018222854A1/en active Application Filing
- 2018-05-31 NZ NZ759513A patent/NZ759513A/en unknown
- 2018-05-31 IL IL270894A patent/IL270894B2/en unknown
- 2018-05-31 BR BR112019025150-2A patent/BR112019025150B1/en active IP Right Grant
- 2018-05-31 KR KR1020197036599A patent/KR102329175B1/en active IP Right Grant
- 2018-05-31 IL IL298034A patent/IL298034B1/en unknown
- 2018-05-31 CN CN201880049949.7A patent/CN110997713B/en active Active
- 2018-05-31 AU AU2018275657A patent/AU2018275657B2/en active Active
- 2018-05-31 JP JP2019565912A patent/JP6963036B2/en active Active
- 2018-05-31 EP EP18733431.3A patent/EP3630814A1/en active Pending
- 2018-05-31 US US15/994,294 patent/US10793624B2/en active Active
- 2018-05-31 CA CA3063588A patent/CA3063588A1/en active Pending
- 2018-05-31 MX MX2019014430A patent/MX2019014430A/en unknown
-
2019
- 2019-11-13 ZA ZA2019/07513A patent/ZA201907513B/en unknown
- 2019-11-14 PH PH12019550238A patent/PH12019550238A1/en unknown
- 2019-11-26 CO CONC2019/0013196A patent/CO2019013196A2/en unknown
- 2019-11-29 CL CL2019003508A patent/CL2019003508A1/en unknown
- 2019-11-29 MX MX2023000390A patent/MX2023000390A/en unknown
-
2020
- 2020-08-28 US US17/006,599 patent/US11767358B2/en active Active
-
2021
- 2021-04-27 JP JP2021074862A patent/JP7162097B2/en active Active
- 2021-10-29 CL CL2021002850A patent/CL2021002850A1/en unknown
- 2021-10-29 CL CL2021002851A patent/CL2021002851A1/en unknown
-
2022
- 2022-01-17 AU AU2022200272A patent/AU2022200272A1/en active Pending
- 2022-09-15 JP JP2022146982A patent/JP7458453B2/en active Active
-
2023
- 2023-08-09 US US18/232,238 patent/US20240083986A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202846B (en) | Human antibodies to fel d1 and methods of use thereof | |
| MX2023000390A (en) | Human antibodies to bet v 1 and methods of use thereof. | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| CA3046387A1 (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| WO2013152001A3 (en) | Anti-hla-b*27 antibodies and uses thereof | |
| WO2011094259A3 (en) | Cd127 binding proteins | |
| EP1603949B8 (en) | Antibodies against human il-21 receptor and uses therefor | |
| EP4219552A3 (en) | Il-11r binding proteins and uses thereof | |
| EP2796469A3 (en) | Novel compositions and methods for treating ige-mediated disorders | |
| WO2015031667A3 (en) | Gitr antigen binding proteins | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| EP2447280A3 (en) | VEGF analogs and methods of use | |
| WO2014012001A3 (en) | Use of cart19 to deplete normal b cells to induce tolerance | |
| NZ596022A (en) | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof | |
| AU2018282094A1 (en) | Antibodies that specifically bind PD-1 and methods of use | |
| WO2020014132A3 (en) | Antibodies binding to ilt4 | |
| MX2016012479A (en) | Binding members to tnf alpha. | |
| WO2011098762A3 (en) | Antibodies against cxcr4 | |
| WO2021127200A8 (en) | Ilt3-binding agents and methods of use thereof | |
| WO2019222679A3 (en) | Methods of isolating allergen-specific antibodies from humans and uses thereof | |
| WO2019098759A3 (en) | Transformed human cell and use thereof | |
| EA201992651A1 (en) | HUMAN ANTIBODIES K Bet v 1 AND WAYS OF THEIR APPLICATION | |
| WO2015077442A3 (en) | Grass pollen immunogens and methods and uses thereof for immune response modulation | |
| WO2015077434A3 (en) | Pan pollen immunogens and methods and uses thereof for immune response modulation | |
| WO2015054217A3 (en) | Methods and uses for reducing an allergic response in a subject |